AML Highlights: Do Gilteritinib & Quizartinib Prolong OS in FLT3-Mutated R/R Disease? CPX-351 vs. CYT+DNR - What to Choose in Newly Diagnosed Disease? Are Ivo/Ena + Aza Beneficial for Chemo-Ineligible Patients?
Comments 0
Login to view comments.
Click here to Login
